Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14264747 | 0.88 | RAB9A (0.57) | ALDH1A1GAATDP1HPGDTP53 | |
| SCHEMBL4075735 | 0.81 | ALDH1A1 (0.61) | ALDH1A1GAAHPGDSMN1; SMN2LMNA | |
| SCHEMBL1490952 | 0.80 | HPGD (0.76) | ALDH1A1TDP1HPGDTP53SMN1; SMN2 | |
| SCHEMBL6659071 | 0.78 | KMT2A (0.58) | ALDH1A1SMN1; SMN2LMNAPOLBKMT2A | |
| SCHEMBL6659077 | 0.78 | KMT2A (0.58) | ALDH1A1SMN1; SMN2LMNAPOLBKMT2A | |
| SCHEMBL14264744 | 0.78 | HPGD (0.50) | ALDH1A1GAAHPGDTP53SMN1; SMN2 | |
| SCHEMBL14279165 | 0.78 | HPGD (0.51) | ALDH1A1TDP1HPGDTP53SMN1; SMN2 | |
| SCHEMBL1106990 | 0.76 | ALDH1A1 (0.60) | ALDH1A1GAATDP1HPGDTP53 | |
| SCHEMBL15731911 | 0.76 | ALDH1A1 (0.57) | ALDH1A1GAATDP1HPGDUSP2 | |
| SCHEMBL15709475 | 0.76 | ALDH1A1 (0.57) | ALDH1A1GAATDP1HPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | ALDH1A1 674/4885GAA 3187/4885TDP1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.